These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18325652)

  • 1. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
    Kato M; Wakeno M; Okugawa G; Fukuda T; Takekita Y; Hosoi Y; Azuma J; Kinoshita T; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1041-4. PubMed ID: 18325652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression.
    Kato M; Wakeno M; Okugawa G; Fukuda T; Azuma J; Kinoshita T; Serretti A
    Neuropsychobiology; 2007; 56(4):167-71. PubMed ID: 18332644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SSRIs antidepressant activity is influenced by G beta 3 variants.
    Serretti A; Lorenzi C; Cusin C; Zanardi R; Lattuada E; Rossini D; Lilli R; Pirovano A; Catalano M; Smeraldi E
    Eur Neuropsychopharmacol; 2003 Mar; 13(2):117-22. PubMed ID: 12650956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients.
    Kato M; Zanardi R; Rossini D; De Ronchi D; Okugawa G; Kinoshita T; Colombo C; Serretti A
    Psychiatry Res; 2009 May; 167(1-2):97-105. PubMed ID: 19361869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
    Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L
    J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
    Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to sertraline is influenced by GNβ3 gene G-350A variant in patients with major depressive disorder.
    Firouzabadi D; Firouzabadi N; Kalani K; Zomorrodian K; Tehrani ES
    Eur J Clin Pharmacol; 2019 Feb; 75(2):189-194. PubMed ID: 30324302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
    Kato M; Fukuda T; Wakeno M; Fukuda K; Okugawa G; Ikenaga Y; Yamashita M; Takekita Y; Nobuhara K; Azuma J; Kinoshita T
    Neuropsychobiology; 2006; 53(4):186-95. PubMed ID: 16874005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder.
    Kishi T; Ichinose H; Yoshimura R; Fukuo Y; Kitajima T; Inada T; Kunugi H; Kato T; Yoshikawa T; Ujike H; Musso GM; Umene-Nakano W; Nakamura J; Ozaki N; Iwata N
    J Affect Disord; 2012 Dec; 142(1-3):315-22. PubMed ID: 22770721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association analysis of SIGMAR1 with major depressive disorder and SSRI response.
    Kishi T; Yoshimura R; Okochi T; Fukuo Y; Kitajima T; Okumura T; Tsunoka T; Kawashima K; Yamanouchi Y; Kinoshita Y; Umene-Nakano W; Naitoh H; Nakamura J; Ozaki N; Iwata N
    Neuropharmacology; 2010 Jun; 58(7):1168-73. PubMed ID: 20178807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
    Zanardi R; Serretti A; Rossini D; Franchini L; Cusin C; Lattuada E; Dotoli D; Smeraldi E
    Biol Psychiatry; 2001 Sep; 50(5):323-30. PubMed ID: 11543734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM; Gao KR; Yu H; Shen YF; Li HF
    J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors.
    Serretti A; Zanardi R; Cusin C; Rossini D; Lilli R; Lorenzi C; Lattuada E; Smeraldi E
    Psychiatry Res; 2001 Nov; 104(3):195-203. PubMed ID: 11728608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
    Yoshimura R; Umene-Nakano W; Suzuki A; Ueda N; Miyamoto K; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    Hum Psychopharmacol; 2009 Aug; 24(6):489-94. PubMed ID: 19606452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders.
    Lee HJ; Cha JH; Ham BJ; Han CS; Kim YK; Lee SH; Ryu SH; Kang RH; Choi MJ; Lee MS
    Pharmacogenomics J; 2004; 4(1):29-33. PubMed ID: 14647404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression.
    Dreimüller N; Tadić A; Dragicevic A; Boland K; Bondy B; Lieb K; Laux G; Maier W; Müller MJ; Rao ML; Rietschel M; Röschke J; Zill P; Hiemke C
    Pharmacopsychiatry; 2012 May; 45(3):108-13. PubMed ID: 22086748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.